Kosiba v. Merck Co Inc

384 F.3d 58, 2004 WL 2029942
CourtCourt of Appeals for the Third Circuit
DecidedSeptember 13, 2004
Docket02-2668
StatusPublished
Cited by1 cases

This text of 384 F.3d 58 (Kosiba v. Merck Co Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kosiba v. Merck Co Inc, 384 F.3d 58, 2004 WL 2029942 (3d Cir. 2004).

Opinion

BECKER, Circuit Judge.

Plaintiff Celeslie Epps-Malloy is a former employee of defendant Merck & Co. (“Merck”), who participated in Merck’s ERISA-based Long Term Disability Plan for Union Employees (the “Plan”). 1 At times relevant, Merck, as overall plan administrator, had delegated responsibility for claims administration to defendant UNUM Life Insurance Company of America (“UNUM”). 2 Following an at-work injury and a diagnosis of sarcoidosis and fibromyalgia, Epps-Malloy applied for and received long-term disability (LTD) benefits from the defendants in 1993. During a periodic review conducted in 1996, the defendants terminated Epps-Malloy’s benefits, finding that she was no longer totally disabled under the terms of the Plan. During the course of the Plan’s administrative appeals process, Merck requested that Epps-Malloy undergo an independent medical examination, and designated a pul-monologist, Dr. Gautam Dev, to evaluate her. Dr. Dev’s report contradicted Epps-Malloy’s treating physicians’ diagnoses, and on this basis the defendants upheld their denial of continued benefits. Epps-Malloy then filed this suit under 29 U.S.C. § 1132(a)(1)(B), seeking benefits allegedly due her under the terms of the Plan.

Epps-Malloy’s claim survived summary judgment, and the District Court held a Fed.R.Civ.P. 52(a) bench trial on a stipulated documentary record. The Court concluded that under Pinto v. Reliance Standard Life Insurance Co., 214 F.3d 377 (3d Cir.2000), and its progeny, the structural arrangement among Merck, the Plan, *61 and UNUM did not warrant' a departure from the traditional “arbitrary and capricious” standard of review over ERISA plan fiduciaries’ discretionary decisions regarding benefits. Turning to the merits of Epps-Malloy’s claim, the District Court found, principally because of Dr. Dev’s report, that the defendants’ denial of benefits was not arbitrary and capricious.

On appeal, we concentrate on the District Court’s first conclusion. We agree with the District Court that the record in this case does not support finding a financial conflict of interest (which, under Pinto's “sliding scale” approach, would warrant a standard of judicial review less deferential than arbitrary and capricious review), and that delegation by Merck to UNUM of claims administration would ordinarily preclude heightened. review. However, there is evidence of procedural bias in Merck’s intervention in the appeals process to request an independent medical exam. This is especially problematic because the record before the defendants prior to Dr.-Dev’s examination provided reasonably sound as well as unequivocal support for Epps-Malloy’s claim for benefits; the choice to request a third medical opinion therefore strongly suggests a desire to generate evidence to counter Epps-Malloy’s physicians’ diagnoses. Because Merck’s- intervention, notwithstanding its delegation of claims administration to a large and experienced carrier, undermines the defendants’ claim to the deference normally accorded an ERISA plan fiduciary with discretionary authority, we conclude that the District Court should have applied a moderately heightened arbitrary and capricious standard of review. Additionally, with respect to the merits, the District Court failed to address Epps-Malloy’s fibromyalgia diagnosis, an omission which itself alone would require a new trial. For these reasons, we will reverse the judgment of the District Court and remand for a new trial.

I. Factual Background and Procedural History

Although the District Court, which rendered its opinion following a Fed.R.Civ.P. 52(a) bench trial on a stipulated documentary record, gave a lengthy account of the parties’ factual contentions, it by and large did not make findings of fact as required by Rule 52(a). As such, what follows is not so much the District Court’s factual findings as it is our own summary of the record before us.

A. ■ Epps-Malloy’s Medical History

Epps-Malloy was employed by Merck as a cook and food-service attendant. She suffered an injury at work in 1991, and was diagnosed with fibromyalgia, chronic pain syndrome, and sarcoidosis. 3 She was granted short-term disability benefits by the defendants in October 1992. In October 1993, she was approved for LTD bene *62 fits, but was reminded that periodic requests for medical information would be made in the future to ensure continued eligibility (i.e., to determine that she continued to be completely disabled under the Plan). Around the same time, Epps-Mal-loy applied for Social Security disability benefits. In 1994, an administrative law judge overruled the Social Security Administration’s (SSA) initial determination denying her Social Security benefits, and awarded her Social Security long-term disability benefits, finding her permanently disabled.

Epps-Malloy’s benefits were provided under the terms of the Merck & Co. Long Term Disability Plan for Union Employees, an ERISA plan. By the Plan’s terms, “[Merck] shall pay the cost of the benefits provided under the Plan,” though the Plan gives discretion to the Management Pension Investment Committee to choose “any funding method, or combination of funding methods which are permissible under ERISA.” The District Court found that no evidence was introduced on how Merck actually funded the plan, and the parties do not dispute this on appeal. The Plan allocates fiduciary responsibility among a committee of Merck’s Board of Directors (which has certain powers of appointment); the Merck Management Pension Investment Committee (which is responsible for the investment and management of Plan funds); and Merck itself, which is the plan administrator. As plan administrator, Merck has the power to appoint a claims administrator, who “shall determine claims for benefits by Participants under the Plan.” At the time Epps-Malloy’s LTD benefits were first granted, Thomas L. Jacob & Associates (“TLJ”) was Merck’s appointed claims administrator; later, ap-pellee UNUM was the claims administrator. Notwithstanding this appointment, the Plan confers on Merck (as plan administrator) the powers “to construe the Plan”; “to decide all questions of eligibility”; and “to request and receive from all Participants such information [as is] necessary for the proper administration of the Plan.”

B. Termination of Epps-Malloy’s LTD Benefits

In May 1996, as part of a periodic review of Epps-Malloy’s benefits, UNUM requested information from her treating physicians, Dr. Panullo and Dr. David Williams. Dr. Panullo was Epps-Malloy’s gynecologist. Epps-Malloy’s disability is not related to any gynecological condition, so Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kosiba v. Merck & Company
384 F.3d 58 (Third Circuit, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
384 F.3d 58, 2004 WL 2029942, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kosiba-v-merck-co-inc-ca3-2004.